Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme
Class ITerminatedD-1350-2022

Drug recall · August 10, 2022

SUSTANGO recall

Why: Marketed Without an Approved NDA/ANDA: Analytical testing showed the presence of tadalafil.

Class I: a reasonable chance the product could cause serious harm or death.

The recall

Product

SUSTANGO (Pendenadril Tytrate Blend) Capsules, 400 mg, 10-count blisters per carton, Formulated by: Male FX Labs, Bangor, ME, ASIN X0024468I9.

Lots / codes

Lot DAP272109, Exp: 4/1/2026

Quantity
750 cartons
Company
Ultra Supplement LLC, Wilmington, DE
Distribution
Product was distributed nationwide in the USA via Amazon Marketplace on www.amazon.com.
Initiated
July 21, 2022 · Voluntary: Firm initiated
Classified
August 17, 2022
Reported
August 10, 2022
Ended
October 16, 2023
How notified
Press Release

If you have this product

  1. Check the lot number on your package against the lots above. Only those lots are recalled.
  2. Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
  3. Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
  4. Return or dispose of recalled product as the company or your pharmacy advises.

Questions about this recall

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.